ABSTRACT: This review summarizes the current data on the effects of smoking and tobacco on the immune system and its potential impact on periodontal health. Smokers are 2.5-6 times more likely to develop periodontal disease than non-smokers, and there is evidence for a direct correlation between the number of cigarettes smoked and the risk of developing disease. Tobacco users also tend to exhibit increased severity of periodontal disease. Direct correlations between tobacco use and increased attachment loss and pocket depth and reduced bone crest height have been reported.
Introduction
Both longitudinal and cross-sectional studies in such diverse locations as upstate New York, suburban Boston, Richmond (VA), North Carolina, and Sweden indicate that cigarette smoking is a significant risk factor for the development of periodontal disease (Beck et al., 1990; Haber and Kent, 1992; Beck, 1994; Bergstrom and Preber, 1994; Haber, 1994a,b; Schenkein et al., 1995; Gonzalez et al., 1996) . A report from Grossi et al. (1994) is particularly striking in that none of 202 heavy smokers (> 30 pack years) studied was periodontally healthy. In a longitudinal study of older adults, Beck et al. (1990) report that smoking is a significant risk factor for both Caucasian and African-American adults. Our own studies of a population in and around Richmond, Virginia, indi- cate that the prevalence of cigarette smoking is higher among both adult periodontitis and severve generalized early-onset periodontitis patients compared with ageand race-matched periodontally healthy individuals (Schenkein et al., 1995) . Studies in both US and Swedish Beck et al., 1990 Boston, MA, USA adults, age 25+ 6.1b Haber and Kent, 1992 Beck and Slade, 1996 a4+ sites with > 5 mM attachment loss; Caucasians/African-Americans. b50% bone loss on one or more surfaces.
cSeverity of attachment loss for heavy smokers pack-years).
d25+ sites with > 4 mM attachment loss; 1982 study/i 992 study.
ePocket depth > 3.5 mM.
populations indicate that the prevalence of cigarette smoking is highest among patients with moderate to advanced periodontal disease (Haber and Kent, 1992; Bergstrom and Preber, 1994) . Risk assessment analyses of data collected in the upstate New York, Boston, North Carolina, and Swedish studies and the follow-up National Health and Nutrition Examination Survey (NHANES) indicate that tobacco users are -2.5 to 6 times more likely to develop periodontal disease than are non-smokers (Table 1 ; Beck et at., 1990; Haber and Kent, 1992; Beck, 1994; Bergstrom and Preber, 1994; Eklund and Burt, 1994; Grossi et al., 1994; Beck and Slade, 1996) . In the North Carolina population, Beck et at. determined that the odds ratios for Caucasian and African-American adults were 6.7 and 2.8, respectively (Beck et al., 1994) . In Caucasians, cigarette smoking has the highest odds ratio of all the risk factors identified, including the presence of P. gingivalis in supragingival plaque (odds ratio = 3.8) and a positive BANA test (odds ratio = 3.6). Similarly, studies in upstate New York, Minneapolis-St. Paul, and Sweden indicate that the odds ratios are higher for cigarette smoking than for the presence of periodontal pathogens (Stoltenberg et al., 1993; Bergstrom and Preber, 1994; Grossi et al., 1994) . Ordinal stepwise regression analysis of the data collected in the upstate New York study indicates that while age is the most signficant risk factor for the development of periodontal disease (the odds ratios range from 1.7 for young adults to 9.0 in the elderly), cigarette smoking has a significant impact on the risk for developing periodontal disease (Grossi et at., 1994) . In fact, the odds ratio for developing peridontal disease increases with the amount of cigarette smoking. The odds ratio for moderate smokers ( 15-30 pack-years) is reported to be 2.77, while heavy smokers (greater than 30 packyears) have an odds ratio of 4.75. At least one study indicates that the effects of smoking on the periodontium are reversible, since smoking cessation is correlated to reduced predisposition to develop periodontal disease (odds ratios = 3.3 and 2.1 for current and former smokers, respectively) (Haber and Kent, 1992) .
In addition to increased incidence, tobacco users tend to exhibit increased severity of periodontal disease (Stoltenberg et al., 1993; Beck, 1994; Bergstrom and 438 Crit Rev Oral Biol Med 8(4):437-460 (1997) 8(4):437-460 (1997) Preber, 1994; Grossi et al., 1994; Haber, 1994a, b; Grossi et al., 1995; Schenkein et al., 1995; Gonzalez et al., 1996) . The presence of cotinine (a stable metabolite of nicotine, t1/2= 10-30 hrs) in the serum is indicative of (1) recent exposure to tobacco and (2) the level of exposure. In the upstate New York population, positive correlations are reported between the levels of serum cotinine and the severity of clinical attachment loss, pocket depth, and bone crest height (Gonzalez et al. 1996) . Other studies have determined that probing depth, attachment loss, and the number of sites with > 4-5 mM attachment loss are increased in smokers compared with non-smokers (Bergstrom and Preber, 1994; Haber, 1994a; Schenkein et al., 1995) . The effects of tobacco and smoking on gingival health remain debatable (Bergstrom and Preber, 1994; Gonzalez et al., 1996) . Interestingly, tobacco users exhibit reduced bleeding on probing compared with non-users (Preber and Bergstrom, 1985) , perhaps due to the vasoconstrictive actions of nicotine (Bounameaux et al., 1988; Michel et at., 1988) .
Tobacco users also tend to respond less favorably to most periodontal treatment modalities (Ah et al., 1994; Haber, 1994b; Preber et al., 1995) . Approximately 90% of patients with refractory periodontitis are cigarette smokers (Bergstrom and Blomlbf, 1992; MacFarlane et al., 1992) . Smokers are reported to exhibit minimal responses to non-surgical procedures such as subgingival debridement (Haber, 1994b; Preber et al., 1995) . Haber reports that despite surgical intervention, smoking patients in a suburban Boston population exhibit re-pocketing within one year of treatment (Haber, 1994a) . In a recent study, Ah et al. (1994) evaluated four periodontal treatment modalities in smoking and non-smoking patients. In these studies, the oral cavity was divided into four regions, and each region was subjected to a different treatment. The treatments ranged from coronal and subgingival scaling and root planing to non-surgical procedures followed by modified Widman surgery or osseous resection surgery. In all cases, smoking patients exhibited reduced changes in probing depth and attachment loss compared with non-smoking patients. Higashimoto et al., 1992 Sauty et al., 1994 Twigg et al., 1994 Janson et al., 1995 Payne et al., 1994 Payne et al., 1994 Pueringer et al., 1993 Suzuki et al., 1993 Aoshiba et al., 1994 Aoshiba et al., 1994 Hersey et al., 1983 Ginns et al., 1985 Hughes et al., 1 985; Phillips et al., 1985; Nair et al., 1990 Hockertz et al., 1994 Francus et ai., 1 988 Sopori et al., 1989; Savage et al., 1991; Goud et a!., 1992 Goud et al., 1993 Francus et al., 1 988 Menard and Rola-Pleszczynski, 1987 Petro et al., 1992 Chang et al., 1990 Johnson et al., 1990 a Smokeless tobacco.
Although the correlation between tobacco use and periodontal disease is quite strong, the exact role of smoking in the pathogenesis of periodontitis is not certain. Cigarette smoke extracts, smokeless tobacco products, and nicotine have deleterious effects on gingival fibroblasts, which could either lead to soft-tissue damage or compromise soft-tissue repair (Lenz et al., 1992; Peacock et al., 1993; Nakamura et al., 1995) . Acrolein and acetaldehyde, components of cigarette smnoke, are two potential mediators of these effects. The presence of periodontal pathogens has been correlated to the development of disease, but most studies suggest that the prevalence of these organisms is similar in smokers and non-smokers (Stoltenberg et al., 1993; Beck, 1994; Grossi et al., 1994; Preber et al., 1995) . However, plasma levels of vitamin C are reduced in cigarette smokers, and this could limit the capacity of phagocytes to control oral pathogens (Tribble et al., 1993; van Antwerpen et al., 1993) . For example, both macrophages and neutrophils from scorbutic guinea pigs exhibit reduced capacities to kill A. viscosus, an oral microorganism (Goldschmidt, 1991) . Furthermore, a recent study indicates that neutrophils from patients with refractory periodontitis (-90% of these are smokers) exhibit reduced capacity to adhere to and ingest periodontal pathogens (Wolff et al., 1994) .
Several studies indicate that the capacity to produce antibodies against periodontal pathogens is compromised in cigarette smokers. A survey of dental patients in suburban Boston indicates that smokers have reduced levels of serum IgG directed against P. intermedia and F. nucleatum (Haber, 1994a) . Recently, our group has shown that in young adults with the severe generalized form of periodontitis (G-EOP), smoking tends to limit the production of IgG2 (Quinn et al., 1996) . This isotype of IgG is associated with the immune response against the carbohydrate antigens that are associated with oral pathogens (Ling et al., 1993) , and it has been suggested that the reduction in IgG2 allows the disease to be disseminated.
Indeed, our unpublished observations indicate that, in
Caucasian adults, the level of IgG2 directed against A. actinomycetemcomitans is lower in smokers compared with non-smokers (Tangada et al., unpublished) .
These data raise the intriguing possibility that the effect of tobacco use on periodontal health is related to its effects on host defense mechanisms (i.e., the immune system). In fact, several recent reviews have suggested that existing risk and prevention models would be strengthened by the inclusion of data on host defense mechanisms (Genco, 1992; Page, 1992; Beck, 1994; Haber, 1994a; Quinn et al., 1996) . Hence, the purpose of this review is to summarize the existing data on the effects of smoking and tobacco on the immune system. It is hoped that this information will facilitate the development of more accurate risk and prevention models for periodontal disease.
The immune system is a complex assortment of cells and soluble molecules that protect higher organisms from microbial invasion. Some aspects of the immune system are innate to an organism: For example, the alternative pathway of complement and natural killer cells have naturally evolved to recognize microbial cells and "altered self' cells, respectively. Other parts of the immune system must be acquired or learned. The development of specific antibodies that recognize foreign proteins and the production of cytotoxic T-lymphocytes directed against invading viruses are examples of acquired immunity. Together, the natural and acquired immune systems maintain the integrity of higher organisms by recognizing and destroying virally infected and transformed (tumor) cells (primarily through cell-mediated immunity), producing specific antibodies which are used to clear micro-organisms from the circulation (primarily mediated by humoral immunity), and providing "immune surveillance" to prevent the growth of tumor cells (primarily mediated by natural killer cells). Given its essential functions, it is clear that chemical or biological agents that interfere with the functioning of the immune system are potentially lethal to higher organisms. Tobacco and smoking are associated with a variety of human disorders, ranging from increased incidence of allergy and asthma to emphysema to lung carcinoma. Hence, it stands to reason that smoking and tobacco may have negative impacts on the functioning of the immune system. The purpose of this review is to enumerate the effects of smoking and tobacco on the functioning of the immune system and to determine how they affect human health and well-being.
"Smokers' leukocytosis", characterized by an increase of 16 to 30% in the white blood cell count, was identified almost 20 years ago. Hence, much of this review focuses on the effects of tobacco and smoking on the leukocytes, the cells that comprise the immune system. Where possible, data are cited to examine the effects of specific components of tobacco (e.g., nicotine), to provide some understanding of the interaction of tobacco and the immune system at the molecular level. We also attempt to distinguish the impact of tobacco (i.e., smokeless tobacco and the health problems associated with its use) from the effects of cigarette smoke and smoking on immune system function (Table 2) . It is likely that the chemical by-products of tobacco combustion interact with the immune system in a manner distinct from the interaction with smokeless tobacco. The limited data on the effects of passive exposure to cigarette smoke on the functioning of the immune system are also presented, with particular attention to the effects of parental smoking on children. Finally, we present some of the growing evidence suggesting that effects of smoking on the immune system are reversed when smoking ceases (see Table 3 ).
Our discussion of the effects of tobacco and smoking on the immune systems begins with summaries of the data regarding the phagocytes (neutrophils and macrophages) that are recruited to the lungs to clear the particulate matter that is associated with cigarette smoke. The focus is then turned to the effects of tobacco products on the lymphocytes associated with natural (NK cells) and acquired (B-and T-lymphocytes) immunity. This is followed by a discussion of the correlations between tobacco smoking and the incidence of allergy and asthma. Finally, the data on the effects of smoking and tobacco on the immune system are summarized in light of some of the other health problems that are associated with tobacco use. Skold et al., 1993 Skold et al., 1993 communication among cells of the immune system. Phagocytic macrophages clear invading micro-organisms and senescent host cells from the circulation. The cytocidal activities of macrophages are involved in the destruction of phagocytized micro-organisms and in the killing of some types of tumor cells. Antigen presentation by macrophages is crucial to antigen-specific responses in both humoral and cell-mediated immunity. Given these critical functions, it is clear that macrophage dysfunction can severly compromise the immune system. The following sections deal with the modulation of macrophage function by tobacco and smoking.
Much of the work in this area has focused on alveolar macrophages (AM), since these cells are directly affected by inhaled tobacco smoke. Typically, the alveolar macrophages of smokers and non-smokers (or animals exposed to tobacco smoke) are recovered by broncho-alveolar lavage (BAL). BAL macrophages can then be cultured and functional assays performed to determine the effects of smoking on macrophage cell biology. In addition, cultured BAL macrophages can be treated with tobacco, tobacco components (e.g., nicotine), or by-products of tobacco smoke to determine the specific effects of these compounds on function. Finally, the broncho-alveolar lavage fluid (BALF) can be assayed for secreted macrophage products (e.g., cytokines, eicosanoids), as an indication of the in vivo functionality of the alveolar macrophages.
EFFECTS OF TOBACCO AND SMOKING ON NUMBERS OF ALVEOLAR MACROPHAGES
Cells recovered in the BALF are representative of the resident cells in the lung. Most studies agree that BALF from smokers exhibits an overall increase in cellularity compared with BALF from non-smokers (Hoogsteden et al., 1991; Merchant et al., 1992; Pessina et al., 1993; McCrea et al., 1994) . Specifically, macrophage cell numbers are elevated in BALF from smokers, indicating an increase in the number of alveolar macrophages in these subjects (Hoogsteden et al., 1991; Pessina et al., 1993; McCrea et al., 1994) . This is confirmed by histochemical studies which show increased numbers of macrophages in sections from smoker lungs (Wallace et al., 1992) . Similarly, animal models suggest that acute exposure to tobacco smoke induces an increase in the number of macrophages recovered in BALF, but no change in the number of macrophages in the peritoneum (Pessina et al., 1993) . These data are in contrast to those from studies in human systems which indicate increased overall cellularity and increased numbers of macrophages in both the BALF and peripheral blood of smokers (Hoogsteden et al., 1991 , Merchant et al., 1992 Hockertz et al., 1994; McCrea et al., 1994; Schwartz and Weiss, 1994) . Interestingly, it has been reported that the increase in cellularity of smoker BALF is resolved when smoking ceases (Skold et al., 1993) .
The increase in macrophage cell number could relate to increased proliferation of smoker AM compared with AM from non-smokers. Murine macrophages incubated with BALF from smokers exhibit increased 13H1-thymidine incorporation compared with cells treated with BALF from non-smokers (Barbers et al., 1991) . Direct demonstration of the increased proliferative capacity of smoker AM is evident in autoradiographic studies of cells labeled with 13H1-thymidine. Although the stimulus for increased proliferation of smoker macrophages has not been identified, one study has shown increased levels of macrophage-colony-stimulating factor (M-CSF) in smoker BALF, and this could relate to the increases in proliferative capacity (Rose et al., 1992) .
Chemotaxis is another potential mechanism for generating increased numbers of macrophages in the BALF of smokers. One possible teleological explanation for chemotaxis of macrophages to the lungs of smokers is that it facilitates the clearance of particulate materials derived from smoke. To this end, one group has demonstrated increased chemokinesis in macrophages from smokers compared with those from non-smokers (which regulates the growth and differentiation of B-lymphocytes), (a chemoattractant for granulocytes), and tumor necrosis factor (TNF, promotes apoptosis or differentiation of target cells). A plethora of in vitro studies has addressed the potential alteration of cytokine production in smoke-exposed macrophages (Higashimoto et al., 1992; Soliman and Twigg, 1992; Sauty et al., 1994; Janson et al., 1995) . Although the results of these studies are not as consistent as the data demonstrating increased numbers of macrophages in smoker BALF, the general consensus is that AM from smokers exhibit reduced cytokine production compared with that from non-smokers. This is especially true for IL-6 and TNF; both basal and LPS-induced production of these cytokines is suppressed in smoker AM (Higashimoto et al., 1992; Soliman and Twigg, 1992; Sauty et al., 1994) . In contrast, there are variable reports of suppressed or unaltered IL-1 secretion by AM from smokers (Sauty et al., 1994; Twigg et al., 1994; Janson et al., 1995) . One study suggests that smoking does not affect the synthesis of IL-1, but rather suppresses its release from AM (Soliman and Twigg, 1992 Crit Rev Oral Biol Med spontaneous and LPS-induced production of TNFcx (Higashimoto et al., 1992; Pessina et al., 1993) . Smokeless tobacco suppresses LPS-induced IL-1a production by peripheral blood monocytes, suggesting that products of tobacco combustion are not required for the suppression of cytokine production (Payne et al., 1994) . Similar results have been reported in an animal model in which mouse AM were exposed to water-soluble tobacco extracts (Higashimoto et al., 1992 the number of macrophages recovered in BALF from human subjects, the levels of prostaglandin E2 (PGE2) are similar in smoker and non-smoker BALF (Pueringer et al., 1993; Hockertz et al., 1994) . Similarly, AM isolated from smokers and non-smokers produce similar levels of both spontaneous and LPS-induced PGE2 and leukotriene B4 (LTB4) (Pueringer et al., 1993; Suzuki et al., 1993 ). In contrast, both smokeless tobacco and nicotine potentiate the capacity of LPS to stimulate PGE2 production by peripheral blood monocytes in in vitro experiments (Payne et al., 1994) . These conflicting data may result from different effects of in vivo vs. in vitro exposure to tobacco and nicotine; it is possible that by-products of tobacco combustion encountered in the in vivo situation prevent the increased PGE2 synthesis that is observed in the in vitro experiments. Alternatively, the absolute levels of nicotine and smokeless tobacco in the in vitro experiments may not accurately reflect the in vivo situation.
There is limited information about the effects of tobacco and smoking on PAF production by macrophages. In an animal model system, BALF from rats exposed to tobacco smoke exhibits decreased levels of PAF compared with that from untreated rats. In addition, this study shows that AM from the smoke-exposed rats express higher levels of a PAF degradative enzyme (PAF acetylhydrolase) and decreased levels of a PAF biosynthetic enzyme (PAF acetyltransferase), suggesting that AM could control the levels of PAF in BALF (Ichimaru and Tai, 1992) . In contrast, in the human system, both chronic and acute smoking result in increases in plasma levels of PAF-like lipids (Imaizumi, 1991 (Ortega et al., 1994) . Phagolysosomes are larger in AM from smokers compared with non-smokers, indicating that, regardless of its effect on phagocytosis, smoking suppresses the catabolism of ingested particles (Lundborg et al., 1995 (Skold et al., 1993; Janson et al., 1995) . The decrease in tumoricidal activity may relate to decreased production of TNFPt by smoker AM (Higashimoto et al., 1992; Sauty et al., 1994; Janson et al., 1995) . One report suggests that although AM from smokers and non-smokers ingest Candida albicans to the same extent, intracellular destruction of the microorganism is suppressed in smoker AM (Sherman et al., 1991) . This could relate to smoking-related decreases in the oxidative burst, which have been reported in PMAstimulated AM (Skold et al., 1993) . Interestingly, the potency of the PMA-induced oxidative burst returns after smoking cessation, suggesting that tobacco or a product of tobacco combustion actively suppresses oxygen metabolism in AM (Skold et al., 1993 In addition, neutrophils are involved in extracellular tissue damage and inflammation. Neutrophils represent the first line of defense against micro-organisms. Hence, compromised neutrophil function is associated with a variety of disorders. Cigarette smoking has been implicated as one of the contributing factors in the etiology of respiratory disease and other disorders. Cigarette smoke contains many oxidants, pro-oxidants, free radicals, and reducing agents. These are capable of reacting with or inactivating essential cellular constituents. Cigarette smoke is also capable of stimulating neutrophils to elaborate a range of oxidants and proteases.
EFFECTS OF TOBACCO AND SMOKING ON NUMBERS OF NEUTROPHILS IN PERIPHERAL BLOOD
Compared with non-smokers, current smokers have significantly increased numbers of peripheral blood leukocytes, particularly neutrophils. The effect of cigarette smoking on circulating neutrophils seems to be acute and reversible. The numbers and percentages of neutrophils in peripheral blood are significantly higher in active smokers than in non-smokers or in the same smokers when they abstain from cigarettes (Noble and Penny, 1975) . These data are corroborated by another study which reports decreases in elevated peripheral blood neutrophil and leukocyte counts within 2 weeks of smoking cessation (Bain et al., 1992) . These data indicate that the abnormalities in these parameters are acute, reversible effects of cigarette smoking rather than responses to tissue damage. Epidemiological studies assessing the relationship of current smoking status to the differential cell counts indicate that the effect of cigarette smoking is not uniform and is primarly influenced by current smoking behavior (Schwartz and Weiss, 1994) . However, long-lasting effects of past smoking are also evident. Neutrophils are also affected by passive smoking. Passive exposure to cigarette smoke is associated with increases in leukocyte counts and in the chemotaxis of and release of reactive oxidants by stimulated neutrophils (Anderson et al., 1991) .
EFFECTS OF TOBACCO AND SMOKING ON NUMBERS OF NEUTROPHILS IN THE LUNG
The transit of neutrophils through the pulmonary vasculature is slowed during inhalation of cigarette smoke in humans. In a rabbit model, smoke exposure increases the retention of neutrophils in the lungs without changing hemodynamics. The neutrophils are randomly distributed in the lobule, and plasma myeloperoxidase is elevated at the beginning of the exposure. Cigarette smoke may damage the lung by activating neutrophils in the pulmonary capillary bed (Bosken et al., 1991 460( 1997) of neutrophils may be due to a smoke-induced decrease in cell deformability (MacNee et al., 1991) . This hypothesis is corroborated by an electron microscopy study which shows that neutrophils from non-smokers are less spherical after exposure to cigarette smoke (Lannan et al., 1992) . Hence, acute cigarette smoke may impair the crucial neutrophil functions of adherence and movement. Together, these data indicate that cigarette smoke promotes systemic priming of neutrophils, although the mechanism remains to be investigated in detail.
EFFECTS OF TOBACCO AND SMOKING

ON NEUTROPHIL CHEMOTAXIS
Activation of the complement system may play a role in directing the influx of neutrophils into the lungs of cigarette smokers. Human serum exposed to cigarette smoke attracts significantly greater numbers of neutrophils compared with normal human serum exposed to air alone. This increase in chemotactic activity is partially attenuated by EDTA but not by EGTA, suggesting that cigarette smoke activates the alternative pathway of complement . One component of the alternative pathway, C5a, is an extremely potent activator of neutrophils, stimulating chemotaxis, adherence, the respiratory burst, and degranulation. C5a also stimulates neutrophils to express adhesins, such as CR3. In addition, C5a has powerful effects on blood vessel walls, causing contraction of smooth muscle and an increase in vascular permeability.
C5a is rapidly degraded to the less potent (approximately 1/1000) chemotaxin C5a des Arg. However, the interaction of C5a des Arg with its co-chemotaxin Gcglobulin (GcG) can restore its chemotactic potency. Therefore, modulation of GcG levels could affect the accumulation of neutrophils in smoking-related diseases. To this end, one study indicates that GcG levels in broncho-alveolar lavage fluids (BALF) are elevated in chronic obstructive pulmonary disease (COPD) patients and asymptomatic smokers compared with non-smokers (Metcalf et al., 1991) . Cigarette smoke has no direct effect on the interaction of GcG with C5a des Arg. However, chemotactic factor inactivator (CFI) can inhibit C5a-directed neutrophil chemotaxis by binding to GcG and inhibiting the capacity of GcG to enhance the chemotactic activity of C5a des Arg. Smoke-treated CFI exhibits a reduced capacity to bind to GcG and hence a decreased capacity to inhibit the binding of C5a des Arg to GcG. CFI in the BALF of asymptomatic smokers and patients with smoking-related COPD exhibits a decreased capacity to inhibit C5a-GcG neutrophil chemotaxis and to bind to GcG . These data indicate that cigarette smoke inhibits chemotactic factor inactivator and that this inhibition could result in the accumulation of neutrophils in the lung. In addition, a recent study indicates that bronchial epithelial cells secrete G-CSF and GM-CSF which markedly increase the survival of human neutrophils in vitro (Cox et al., 1992 (Doherty and Janusz, 1994) .
The levels of (xl-PI in the circulation of patients with inherited ax l-PI deficiencies are -85% lower than those in normal individuals. These patients tend to develop emphysema at an early age, because the imbalance between HNE and ctl-PI leads to tissue destruction (Travis and Salvesen, 1983). Since both cigarette smoke and neutrophils are rich sources of oxidants, oxidation and inactivation of cxl-PI in the lung fluid of smokers could lead to emphysema. Activated neutrophils from patients with stable emphysema produce more 02-than those from healthy controls, especially in smoking subjects (Renkema et al., 1993) . The 02-produced by neutrophils may inactivate cxl-PI and lead to increased HNE activity. This hypothesis is supported by the observation that the kinetics of HNE inhibition is approximately two times slower for cx l-PI purified from the BALF of asymptomatic smokers compared with a l PI from non-smokers (Ogushi et al., 1991) . Numerous studies have reported the inactivation of (xl-PI by cigarette smoke and neutrophils. Thus, smoking-related increases in the numbers of neutrophils in the lungs may be directly involved in the etiology of emphysema. However, it is evident from studies in experimental emphysema that protease/antiprotease (HNE/a1-PI) imbalance is not the only pathological mechanism for emphysema. There is strong evidence that human centrilobular and panacinar emphysema have different etiologies, and some studies suggest that macrophages as well as neutrophils may participate in elastolysis (Snider et al., 1994 However, neutrophil-derived reactive oxidants are also potential carcinogens which directly damage DNA and compromise DNA repair mechanisms. A recent study with cultured human lung cells indicates that tar extract alone does not cause DNA single-strand breaks (DNA-SSB), while activated neutrophils or H 202 will cause a small but significant increase in DNA-SSB. However, if cells are first treated with tar extract and then exposed to activated neutrophils or H20 2 the incidence of DNA-SSB increases considerably (Leanderson and Tagesson, 1994) . Thus, the neutrophils that accumulate in the lungs of smokers may be directly involved in carcinogenesis.
EFFECT OF NICOTINE ON NEUTROPHILS
Nicotine is a major component of cigarettes. Several studies have focused on the relationship of nicotine to neutrophils. Davies et al. (I1982) have characterized a noncholinergic nicotine receptor on human phagocytic leukocytes. The average affinity + standard deviation of (d, I)-nicotine for the receptor on neutrophils is 36 ± 18 nM (n -6). The binding is saturable with an average of 8.7 x 104 sites per neutrophil. Bound nicotine is dissociable from the receptor and is not metabolized. Only close structural analogs of nicotine bind to the receptor, which is stereoselective for the (d)-isomer. The receptor can be occupied by nicotine at concentrations present in the blood of smokers. Thus, the adverse effects of smoking on neutrophil function may be mediated by this or another specific nicotine receptor.
The vertical filtration technique measures membrane resistance, the ability of neutrophils to pass through a micropore membrane. This is a measure of the ability of the cells to change shape and may be related to the retention of neutrophils in the lungs and other tissues. A recent study focuses on the "deformability" and "filterability" of neutrophils after exposure to nicotine and cigarette smoke (Aoshiba et al., 1994) . Neutrophils exposed to gas-phase cigarette smoke (from which almost all the nicotine has been removed) exhibit higher membrane resistance than cells exposed to whole smoke. In addition, there is a negative correlation between membrane resistance after exposure to whole smoke and the nicotine content of the cigarettes tested.
Furthermore, the addition of nicotine to gas-phase smoke prevents the increase in membrane resistance that is normally observed following exposure of neutrophils to gas-phase smoke. These results show that nicotine opposes the smoke-induced increase in membrane resistance, possibly by scavenging the oxidants present in the cigarette smoke. Decreased membrane resistance in this assay is associated with an increase in the ability to change shape and may correlate with the extravasation of neutrophils in vivo.
Nicotine is also chemotactic for human neutrophils. In contrast to most othei-chemotactic molecules, nicotine does not affect superoxide production. The concentration of nicotine experienced by neutrophils during acute cigarette exposure to cigarette smoke is sufficient to stimulate neutrophil F-actin formation and intracellular calcium mobilization, two early events in neutrophil motility (Ryder, 1994) .
CONCLUSIONS
Smokers exhibit increased numbers of neutrophils in both the peripheral blood and the lung. The mechanisms for these increases are not completely resolved, but probably relate to increases in chemotactic agents and an altered ability of the cells to undergo the shape changes that are necessary for diapedesis across the endothelial cell layer. Some recent data indicate that the shape change may be modulated by the binding of nicotine to receptors in the neutrophil plasma membrane. Neutrophils from smokers exhibit enhanced oxygen metabolism and dysfunctional regulation of extracellular proteases, and these alterations may be involved in the etiologies of such smoking-related disorders as emphysema and lung cancer. (Tollerud et al., 1991 437-460( 1997) smoking (Tollerud et al., 1989a) . One study reports that smokers and ex-smokers have 25% fewer NK cells (relative to the circulating lymphoid cell pool) than nonsmokers (Tollerud et al., 1989a) . The same group reports that African-American smokers and non-smokers exhibit similar numbers of NK cells. The authors suggest that the difference in smoking intensity between Caucasians and African-Americans (African-American smokers reported smoking fewer cigarettes per day) cannot account for the race-specific differences in NK cell proportion in smokers. The difference may be genetically based, since several other immunological differences between Caucasians and African-Americans have been reported, including WBC count, numbers of T-and Blymphocytes, and serum IgG and IgE levels (Mili et al., 1991) .
EFFECTS OF TOBACCO AND SMOKING
ON NK CELL CYTOLYTIC ACTIVITY The lytic capacity of NK cells varies from study to study, but the general consensus is that cigarette smoking reduces peripheral blood NK cell cytotoxic activity (Ginns et al., 1985; Hughes et al., 1985; Phillips et al., 1985; Nair et al., 1990) . Compared with cells isolated from nonsmoking subjects, peripheral blood NK cells from subjects smoking at least one pack-year exhibit reduced cytolytic activity against a variety of target cells (Hughes et al., 1985) . It is also reported that NK cells isolated from the BALF of smokers exhibit reduced cytotoxic activity compared with BALF NK cells from non-smokers (Takeuchi, 1988) . Both antibody-mediated (antibodydependent cellular cytotoxicity or ADCC) and non-specific cytolytic functions of NK cells are reported to be inhibited by tobacco and smoking (Hughes et al., 1985) . NK cell activity in heavy smokers (more than 50 packs/year) is reported to be significantly reduced compared with that in non-smokers and light smokers (fewer than 49 packs/year) (Phillips et al., 1985) . Non-smokers and light smokers exhibit similar levels of NK cell activity (Phillips et al., 1985) . However, NK cell activity in heavy smokers is reduced and is similar to that of patients with lung carcinomas (Takeuchi, 1988) .
The reduction in NK cell cytotoxic activity in smokers is reported to be reversible when they stop smoking. A recent report shows that smokers who abstain from smoking for 31 days exhibit higher levels of peripheral blood NK cell activity than smokers who continue to smoke during the same period (Meliska et al., 1995) . Indeed, others have reported that NK activity is indistinguishable between ex-smokers and non-smokers (Hughes et al., 1985) . Several studies suggest that NK cell activity returns to normal levels and that cytolytic activity against cultured melanoma cells increases within three months of smoking cessation (Hersey et al., 1983; Hughes et al., 1985) . These data are in contrast to the studies cited above which indicate that the numbers of peripheral blood NK cells do not recover when subjects cease smoking (Tollerud et al., 1989a) . Although NK activity increases after the cessation of smoking, this does not correlate with decreased levels of nicotine and cotinine in the plasma (Hersey et al., 1983; Hughes et al., 1985) . These (Hughes et al., 1985) . CONCLUSIONS Since B-cells are the sole source of antibodies, antigen-specific activation, growth, and differentiation of these cells are vital for humoral immunity and the development of the acquired immune system. The following section addresses the effects of smokeless tobacco and smoking on B-cell growth and differentiation.
EFFECTS OF TOBACCO AND SMOKING ON IMMUNOGLOBULIN LEVELS IN SERUM
Studies suggest that smoking reduces the concentration of immunoglobulin G (IgG) in human serum. This is a fairly consistent finding in a number of studies performed with human subjects from such diverse locations as the United States, the United Kingdom, Sweden, and Australia (Ferson et al., 1979; Gulsvik and Fagerhol, 1979; Anderson et al., 1982; Hersey et al., 1983; Robertson et al., 1984; McSharry et al., 1985; Quinn et al., 1996) . The overall decrease in serum IgG in smokers has also been noted in epidemiological studies of people receiving the hepatitis B vaccine. Numerous reports indicate that the frequency of response to the vaccine is lower in smokers compared with non-smokers, and that seroconversion occurs more rapidly in non-smokers (Struve et al., 1992; Roome et al., 1993) . The levels of IgG in serum tend to increase when subjects stop smoking (Gulsvik and Fagerhol, 1979; Hersey et al, 1983; Robertson et al., 1984; McSharry et al., 1985) .
Recently, we extended these studies to examine the effects of smoking on the levels of IgG subclasses in the serum of young adults (Quinn et al., 1996) . The Caucasian people and in Caucasian patients with generalized early-onset periodontitis (G-EOP). Serum IgG2 levels in African American subjects do not appear to be affected by smoking, with the single striking exception of African-American subjects with G-EOP. Interestingly, the levels of antibody reactive with Actinobacillus actinomycetemcomitans in smoking African-American G-EOP patients are reduced compared with those in non-smoking African-American G-EOP patients (Tangada et al., unpublished). Thus, in previous studies indicating that smoking reduced serum IgG levels where the patient populations were primarily Caucasian, the reduction in serum IgG was probably due to a reduction in IgG2.
There are conflicting data regarding the influence of cigarette smoking on the levels of serum IgA and IgM. While some reports suggest that smoking suppresses serum levels of IgM and IgA (Gulsvik and Fagerhol, 1979; Hersey et al., 1983; Robertson et al., 1984) , others indicate that one or another of these isotypes is not affected by smoking (Ferson et al., 1979; Anderson et al., 1982; McSharry et al., 1985) . The effects of smoking on serum IgE and allergy are discussed in another section of this review.
The reduction in serum Ig levels can actually be beneficial to some smokers. Smokers exposed to pigeon antigens exhibit a reduced incidence of extrinsic allergic alveolitis, an Ig-related disorder (McSharry et al., 1985; Reynolds et al., 1991) . Given the data cited above which suggest that Ig production is compromised in smokers, one might predict that smokers would exhibit significantly lower antibody responses to the inhaled pigeon antigens that are associated with this disease. Indeed, smokers have lower levels of total serum IgG and IgA than non-smokers exposed to the same amounts of pigeon antigens (McSharry et al., 1985) .
EFFECTS OF TOBACCO AND SMOKING ON B-LYMPHOCYTE FUNCTION Although the levels of serum IgG are reduced, the proportion of B-cells in the peripheral blood leukocytes of smokers is similar to that in non-smokers (Moszczynski et at., Sopori et al., 1989) . Hence, the reduction in serum immunoglobulin is not related to a decrease in the number of potential antibody-producing cells.
However, in vitro experiments indicate that B-cells isolated from smokers' peripheral blood have reduced proliferative responses to both polyclonal B-cell activators (mitogens) and antigens (Sopori et al., 1989; Savage et al., 1991; Goud et al., 1992 ( 1997) heavy smokers and express the HLA-DR7 major histocompatibility antigen (Gairola et al., 1989; Moszczynski et al., 1989) . These patients have tremendously expanded peripheral B-cell populations and high levels of polyclonal IgM in their sera. The surface phenotypes of the Bcells in these patients are similar to cells transformed with Epstein Barr Virus (EBV), in that they express high levels of B-cell activation markers (CD25, CD23, and CD54) (Gairola et al., 1989; Moszczynski et al., 1989 ). As will be noted later in this section, tobacco contains at least one B-cell mitogen, and it is possible that patients with PPL respond to this molecule.
Experiments in rat and mouse model systems support the hypothesis that Ig production and B-cell function are compromised in smokers. Leukocytes from smoke-exposed animals exhibit attenuated proliferative responses to both B-cell mitogens and antigens (Sopori et al., 1989; Savage et al., 1991; Goud et al., 1992; Hockertz et al., 1994) . The decrease in the proliferative response to antigen is not due to a reduction in the number of antigen-specific B-cells in the smoke-exposed animals (Savage et al., 1991) . Hence, smoke-exposed B-cells must be functionally compromised. The effects of smoke on Bcells are reversible, since cessation of smoke exposure is associated with the restitution of normal immune function (Mili et al., 1991; Reynolds et al., 1991) . Kinetically, the decrease in antigen-induced proliferation occurs first in B-cells from lung-associated lymph nodes and then spreads to other lymphoid tissues with prolonged exposure to tobacco smoke (Sopori et al., 1989) . This observation suggests that the reduction in B-cell response may be mediated by by-products of the combustion of tobacco.
Interestingly, tobacco glycoprotein (TGP), a polyphenolic protein in tobacco, is a potent B-cell mitogen (Francus et al., 1988) . TGP induces the proliferation of peripheral and cord blood leukocytes and stimulates the production of IgM, IgG, and IgA (Francus et al., 1988) . These observations are corroborated by in vitro studies with smokeless tobacco (ST), which stimulates the proliferation of mouse spleen and mesenteric lymph node cells and induces the production of polyclonal IgM (Hockertz et al., 1994) . It is possible that these effects of ST are mediated by TGP. Together, these data support the hypothesis that the immunosuppressive effects of smoking are mediated by by-products of the combustion of tobacco. Chronic immunostimulation by ST in the oral mucosa may be linked to the increased incidence of gingivitis, leukoplakia, and oral cancer in ST users.
CONCLUSIONS
The data reported to date indicate that cigarette smoking is associated with the suppression of B-cell function and Ig production. B-cells from smokers exhibit reduced proliferative capacity and reduced Ig production in response to both antigen-specific and non-specific stimuli. Some reports indicate that smoking has variable effects on different isotypes of Ig, suggesting that tobacco smoking may affect Ig class-switching. This possibility-together with the observation that smoking compromises B-cell function, not the number of B-cells-raises the possibility that the effects of smoking and tobacco on immunoglobulin production are mediated primarily at the level of the T-cell. The effects of smoking and tobacco on T-lymphocyte function will be addressed in the next section. Finally, it is important to note that while Bcell function is suppressed in smokers, both smokeless tobacco and a component of smokeless tobacco (tobacco 
EFFECTS OF TOBACCO AND SMOKING ON THE NUMBERS OF T-LYMPHOCYTES IN PERIPHERAL BLOOD AND BALF
The effects of tobacco and smoking on the numbers of peripheral blood T-cells are controversial. Most of these studies focus on the number of CD4+ (helper) T-cells, and variable reports of decreased, increased, or no changes in the numbers of these cells are available Miller and Ginns, 1982; lezewska et al., 1990; Johnson et al., 1990; Chavance et al., 1993 (Tollerud et al., 1991) . In contrast, several studies suggest that smoking increases the number of peripheral blood CD4+ cells in Caucasians (Tollerud et al., 1989b; lezewska et al., 1990) . In both races, correlations between the number of cigarettes smoked per day and the proportion of CD4+ cells have been reported (Mili et al., 1991) . The effects of smoking on peripheral blood T-cells appear to be reversible, since the numbers of CD4+ cells in the peripheral blood of smokers return to the levels observed in people who have never smoked within 2-5 years of smoking cessation (in those studies which report smoking-related changes in T-cell number) . The observation that respiratory but not systemic infections are significantly more frequent among smokers than non-smokers suggests that the effects of smoking on immune function may be localized to the lung and its associated lymph nodes (Finklea et al., 1971) . To this end, it is interesting to note that reports of altered Tcell numbers in the BALF of smokers are more consistent than the results in peripheral blood. In general, the total number of lymphocytes in BALF is elevated in smokers, but the proportion of CD4+ cells is reduced (Costabel et al., 1986; Wallace et al., 1994) . Hence, the ratio of helper to cytotoxic T-lymphocytes (CD4/CD8 ratio) is lower in smoker than in non-smoker BALF. Indeed, one group has reported that while the CD/CD8 ratio is reduced in smoker BALF, the CD4/CD8 ratios in peripheral blood are similar in smokers and non-smokers (Ancochea et al., 1993 , Wallace et al., 1994 .
EFFECTS OF SMOKING AND TOBACCO ON T-LYMPHOCYTE FUNCTION
It is a relatively consistent observation that chronic exposure to cigarette smoke reduces the proliferative response of peripheral blood and BALF lymphocytes to both antigens and T-cell mitogens (Chang et al., 1990;  lohnson et al, 1990 ). These observations have been made in both human systems (which compare the responses of lymphocytes isolated from the peripheral blood of smokers and non-smokers) and in smokeexposed animal models. It is possible that the effects of smoking on T-cell function are tissue-specific. In a rat model system, chronic inhalation of cigarette smoke inhibits the antibody response of lung-associated lymph nodes but not of other, anatomically distant, lymph nodes (Sopori et al., 1989) . Another study shows that smoke inhalation decreases the antigen-induced proliferation of T-cells localized to the tracheobronchial lymph nodes that drain the lung, but has no effect on Tcells from distal lymph nodes (Chang et al., 1990) . These results suggest that both T-and B-cell function in lungassociated lymphoid tissue may be inhibited in smokers, leading to a predisposition to the development of respiratory tract infections.
Interestingly, the opposite effect is observed when Tcells from non-smokers are cultured with smokeless tobacco (ST) (Goud et al., 1993) . Similar to its effect on Bcells, ST is a potent T-cell mitogen and stimulates the incorporation of 13HI-thymidine by both CD4+ and CD8+ T-cells. It is likely that the mitogenic effect of ST is due to tobacco glycoprotein (TGP), which has been shown to enhance the proliferative capacities of both B-and Tlymphocytes (Francus et al., 1988) . It is possible that TGP is denatured when tobacco is combusted, and this may explain the discrepancy between the effects of smoking and ST on T-cell proliferation. Alternatively, by-products of tobacco combustion may actively inhibit the response of T-cells to mitogens and antigen. It is also possible that the immunosuppressive effects of smoking are mediated by nicotine. In vitro experiments with peripheral blood leukocytes from non-smokers indicate that nicotine attenuates the proliferative response of T-cells to mitogens and may induce a population of T-cells which actively suppress T-cell function (Menard and RolaPleszczynski, 1987; Petro et al., 1992) . Finally, it is interesting to note that some studies suggest that acute exposure to tobacco smoke is immunostimulatory, while chronic exposure results in immunosuppression (lohnson et al., 1990) . Together, these data highlight the problem of generalizing with respect to the effects of tobacco and smoking on the immune system. 
EFFECTS OF SMOKING AND TOBACCO ON T-LYMPHOCYTE CYTOKINE PRODUCTION
Limited data are available on the effects of smoking and tobacco on the production of cytokines by T-lymphocytes. Given the inhibitory effect of smoking on the proliferative response of T-cells to both mitogens and antigens, one might predict that smokers' T-cells would produce smaller amounts of cytokine than T-cells from nonsmokers. However, at least one study indicates that PHAinduced IL-4 production is elevated in T-cells from smokers (Byron et al., 1994) . This elevation is consistent with the increased levels of serum IgE and incidences of atopy that are associated with cigarette smoking (O'Connor et al., 1989; Criqui et al., 1990; Bonnin et al., 1991; Jensen et al., 1992; Ericsson et al., 1993) . In addition, there are reports that IL-2 production is elevated in splenic T-cells isolated from rats infused with nicotine (Petro et al, 1992) . The mechanism for the nicotine-induced increase in IL-2 production is uncertain. It is possible that nicotine has indirect neuro-endocrine effects. Acute administration of nicotine increases the levels of ACTH and corticosterone in plasma, and these hormones have been shown to be immunomodulatory in vivo (Blalock and Smith, 1980; Cam and Basset, 1983) . It is also possible that T-cells express nicotine receptors and that the binding of nicotine to these receptors induces T-cell activation.
Since IL-2 stimulates T-cell blastogenesis, these observations are inconsistent with both the decreased Tcell mitogenesis and the reduced humoral immune response that are observed in smokers. The discordant data on T-cell proliferation and IL-2 production may be explained by data from other studies which indicate that the levels of soluble IL-2 receptor (sIL-2R) are higher in smoker than in non-smoker sera (Ginns et al., 1990; Tollerud et al., 1992 Tollerud et al., , 1994 Tollerud et al., , 1995 . It is possible that sIL-2R sequesters IL-2 from the T-cells in smoker sera and hence limits both their proliferative capacity and their ability to provide help to B-cells.
CONCLUSIONS
The current data suggest that smoking has an immunosuppressive effect on T-lymphocytes, particularly on those which are localized to lung-associated lymph nodes. Smoke-exposed T-cells exhibit reduced proliferative responses to both antigen-specific and non-specific stimuli. This observation may be related to the increased levels of sIL-2 receptor that are observed in the sera of smokers. Similar to the situation with B-lymphocytes, the effects of tobacco and smoking on T-cells are discordant. While exposure to tobacco smoke inhibits the mitogenic response of T-cells, ST and TGP (a component of ST) are potent T-cell mitogens. These observations, again, point out the danger in making generalizations about the effects of smoking and tobacco on lymphocytes. Several studies indicate that the ratio of CD4+/CD8+ T-cells is reduced in smoker BALF. Since CD4+ T-cells of the Th2 subtype provide essential "help" to B-cells, it is likely that the reduced antibody response seen in cigarette smokers is at least partially attributable to decreased T-cell function. Increased serum IgE is considered to be a marker of allergic disease, with the caveat that many factors-including age, sex, smoking, and occupation-must be considered in the determination of "normal" levels. There is also a strong association between asthma and serum IgE levels, although the association with specific allergies is not clear.
Asthma and airways hyperresponsiveness are two closely related phenomena, both of which appear to be influenced by smoking and allergy and serum IgE levels (O'Connor et al., 1989; Weiss et al., 1993) . Finally, many studies have concluded that there is a relationship between serum IgE levels and the deterioration of lung function, with possible consequences related to the pathogenesis of chronic obstructive pulmonary disease (COPD) (Villar and Holgate, 1995 Criqui et al., 1990; Bonnin et al., 1991; Jensen et al., 1992; Ericsson et al., 1993) . This effect seems to be more common in males than in females (Barbee et al., 1987; Criqui et al., 1990; Bonnin et al., 1991; Jensen et al., 1992; Shirakawa et al., 1992) , and there is a dose-response relationship in the sense that increased pack-years correlate with increased IgE levels (Criqui et al., 1990; Jensen et al., 1992; Shirakawa et al., 1992; Sherrill et al., 1994) . In addition, one study excludes genetic factors by assessing IgE levels in monozygotic twin pairs who are discordant for smoking. It was found, as in other studies, that smokers have elevated serum IgE levels (Ericsson et al., 1993) . Even ex-smokers have higher IgE levels than never-smokers; however, unlike the situation in current smokers, IgE levels in this group decrease with age (Shirakawa et al., 1992) . This observation has been supported in an animal study (rats) where exposure to smoke raises serum IgE levels (Zetterstrom etal., 1985) .
An interesting, although inconsistent, finding is that cord blood IgE levels can sometimes be shown to be elevated due to parental smoking (Magnusson, 1986; Flores et al., 1993; Bergmann et al., 1995) . In studies that have shown this association, the IgE levels are generally highest when the mother or both parents smoke during preg- (1997) nancy, with lower levels noted if only the father smokes. Some such studies have also shown a correlation between cord blood IgE and smoking dose (Flores et al., 1993) . It should be noted, however, that other studies have failed to demonstrate this phenomenon, even when cord blood cotinine levels were elevated in babies of smoking mothers (Oryszczyn et at., 1991; Ownby et al., 1991; Bjerkeetal., 1994) .
It has been of recent interest to examine the effects of environmental tobacco smoke (passive smoking) on allergic responses in children due to the apparent increase in risk for asthma in children of smoking parents. Several studies ha,,/e demonstrated that, in children with respiratory allergies, IgE levels are highest if both parents are smokers than if one or neither parent smoked (Atici et al., 1994) . Other studies have shown that the prevalence of a positive skin test to common allergens is higher in children passively exposed to parental smoking than in children of non-smokers (Kuchta et al., 1989 , Ronchetti et al., 1992 . The preponderance of the literature in this area to date thus indicates that children exposed to smoke experience more allergies and elevated serum IgE.
The explanation for the increased levels of IgE in serum is not entirely clear, but several possibilities exist:
(a) The increased IgE may be comprised of specific antibodies due to the development of allergies in adult smokers. This would occur due to the increase in permeability of the bronchial epithelium (known to occur in smokers), facilitating ingress for allergens into the lymphoid system. This possibility has been supported by a number of investigators. It appears that, on the average, smokers do not demonstrate increased hypersensitivity responses to typical allergens (Freidhoff et al., 1966; Gautrin et al., 1994; Mensinga et al., 1994; Nielsen et al., 1994i However, sev- eral studies show that smokers are more rone than nonsmokers to develop allergic responses t. ntigens in the workplace, with possible development asthma-like symptoms. Recent studies have showi. increased IgE responses in workers exposed to antigens from such diverse sources as prawns, platinum salts, pharmaceuticals such as laxative ingredients, and solvents (Venables et at., 1985 (Venables et at., , 1989 McSharry and Wilkinson, 1987; Finnegan et al., 1991; Marks et al., 1991; McSharry et al., 1994) . In addition, elevation in serum IgE in response to Streptococcus pneumoniae has been observed in smokers; since this organism is a common inhabitant of the lower respiratory tract, it has been suggested that this increased IgE resp ,nse is a reflection of the increased permeability of the respiratory tract in chronic bronchitis seen in mar y smokers (Bloomr-et al., 1986) . Whether smoking influences the prevalence of allergies to commonly encountered antigens such as pollen and ragweed is less clear; some studies have shown no effect, while others have demonstrated increased conversion to atopy in adult smokers compared with non-smokers (Marks et at., 1991; Lin et al., 1994) . Finally, although isolated instances of allergic reaction to tobacco constituents such as nicotine have been reported, this is very uncommor, (Bircher et al., 1991 
EFFECTS OF TOBACCO AND SMOKING ON LEVELS OF THE CYTOKINE THAT CONTROL IGE PRODUCTION
IgE production is a complex process which is regulated by antigen-specific and non-antigen-specific factors, as well as by external environmental factors. Allergen induction of IgE antibody requires Ig class-switching, which is regulated both by cytokines and by B-cell contact with T-helper cells. The cytokines which regulate and direct IgE isotype switching are IL-4 and IL-1 3, while the interaction of CD40 with its ligand on T-cells provides a second signal for class-switching. Other cytokines involved in this process include IL-5, which promotes class switching to IgE, and IFN-y, which is inhibitory. Finally, high-affinity and low-affinity IgE receptors (FcERI and FcERII) are important in the control of IgE serum levels.
Very few published studies have examined the fundamental effects of smoking on the regulation of IgE production and antibody responses. A recent study compares the production of IL-4 by lymphocytes from smokers and with that from non-smokers (Byron et al., 1994) . Interestingly, production of IL-4 is greater in cells from smokers than in those from non-smokers, while IFN-y levels are not affected by smoking status. These results are consistent with an explanation for increased IgE levels in smokers involving cytokine-mediated enhancement of class-switching to IgE by IL-4, and could account for increases in allergic responses in children exposed to passive smoke.
Other studies have examined the influence of specific tobacco and smoke constituents on cytokine production and IgE synthesis. Both nicotine and cotinine induce increased production of IL-Ix, IL-2, IL-3, (Fischer and Konig, 1994) . Increases in serum IL-2 receptor have been noted in smokers compared with non-smokers (Tollerud et al., 1992) . Finally, levels of leukotriene B4 (LTB4) are higher in sera of non-allergic smokers than in that of non-smokers with or without allergies (Yanagisawa and Nagai, 1993 (Magnusson, 1986; Angioni et al., 1989; Kuchta et al., 1989; Ronchetti et a!., 1990 Ronchetti et a!., , 1992 . What is not clear is whether the effects of smoking on airways responsiveness are mediated through its alterative effects on serum IgE levels or allergic responsiveness, or via other mechanisms such as increased airways inflammation and general reduction in lung function. Since IgE will be elevated in any airway inflammatory process, including active or passive cigarette smoking, smoking could be another mechanism besides allergy to explain the association between IgE and asthma.
There appears to be a difference between children and adults with regard to the association between smoking and asthma. Smoking in adults is a significant predictor of development of asthma, while allergy is a much better predictor of asthma in children than it is in adults. This observation may be due to multiple factors, including the decrease in skin test reactivity noted with increased age (Weiss et al., 1993 (Bosken et al., 1991) . ROI have been shown to induce single-strand breaks in DNA (especially in the presence of tobacco tar), and these breaks may be causally related to carcinogenesis (Leanderson and Tagesson, 1994) . Alternatively, smoking could be related to the progression of lung cancer by limiting the ability of the immune system to identify and destroy tumor cells. NK cell activity and probably numbers are reduced in cigarette smokers compared with non-smokers (Ginns et al., 1985; Hughes et al., 1985; Phillips et al., 1985; Tollerud et al., 1989a; Nair et al., 1990 (Sopori et al., 1989; Chang et al., 1990; lohnson et al., 1990; Savage et al., 1991; Goud et al., 1992) , it is likely that the production of tumor-specific antibodies and antibody-dependent cellular cytolysis (ADCC) of tumor cells are compromised as well. Finally, abert rant T-cell function in cigarette smo-F kers could result in reduced induction of tumor-cell-specific cytotoxic T-lymphocytes and hence to the loss of this mechanism for tumor cell destruction.
MICROBIAL INFECTIONS
The incidence of lower respiratory tract infections (but not systemic infections) is increased in cigarette smokers, indicating that the immune response to inhaled micro-organisms may be compromised. Macrophages mediate the Merchant et al., 1992; Pessina et al. 1993; McCrea et al., 1994; Ortega et al., 1994; Wallace et al., 1994) . Therefore, the ability to clear micro-organisms may be compromised in the lungs of cigarette smokers. Furthermore, through its impact on B-and T-cell function, smoking results in decreased levels of the specific antibodies that aid in phagocytemediated clearance of micro-organisms (Gulsvik and Fagerhol, 1979; Anderson et al., 1982; Haber, 1994a; Quinn et al. 1996) . Decreases in the levels of micro-organism-specific antibodies in the BALF result in reduced opsonization and hence to reduced binding to and phagocytosis by macrophages. It will also be of interest to identify the genes or gene products that are directly affected by tobacco and smoking. Along these lines, it is interesting to note the apparent racespecific effects of smoking on natural killer cells and immunoglobulin production (Tollerud et al., 1989a; Quinn et al., 1996) . Furthermore, at least one study indicates that the odds ratios for smokers developing periodontal disease are different in Caucasians and African-Americans (Beck et al., 1990) . In future studies, these racial differences may be exploited to determine the genetic factors that are affected by smoking and tobacco.
Several studies indicate that tobacco and the by-products of tobacco combustion (i.e., smoking) may have divergent effects on the immune system (Francus et al., 1988; Sopori et al., 1989; Chang et al., 1990; Johnson et al., 1990; Goud et al., 1992; Petro et al., 1992; Hockertz et al., 1994 ; Table  2 ). These data highlight the need to identify the specific chemicals in tobacco and tobacco smoke that interact with cells of the immune system.
Finally, although the effects of passive smoking have received a lot of attention in recent years, few studies have addressed its impact on the functioning of the immune system or on periodontal health. Given the current "anti-tobacco" climate in the United States, this is certain to be an active area of research in the future.
It is important to note that the factors that regulate the development and progression of periodontal disease are inter-related. For example, environmental factors could limit the host responses that are necessary to control oral pathogens. This review has focused on tobacco use, an environmental factor that has a negative impact on cells of the immune system. This, in turn, undermines host response mechanisms and leads to the development and progression of periodontal and other diseases. Collectively, the morbidity and mortality associated with these diseases are staggering. In the current climate of declining health care dollars and reduced access to health care, tobacco use represents a significant public health problem which demands attention from the research community.
